Table 1. Clinicopathologic demographics of included patients before and after Propensity Score Matching.
Variables | Before PSM | After PSM | |||||||
---|---|---|---|---|---|---|---|---|---|
Total (N=803) | Non-TD (N=666) | TD (N=137) | P value | Total (N=411) | Non-TD (N=274) | TD (N=137) | P value | ||
Gender, n (%) | 0.819 | 0.626 | |||||||
Male | 543 (67.6) | 452 (67.9) | 91 (66.4) | 281 (68.3) | 190 (69.3) | 91 (66.4) | |||
Female | 260 (32.4) | 214 (32.1) | 46 (33.6) | 130 (31.7) | 84 (30.7) | 46 (33.6) | |||
Age, median (IQR) | 57 [49–66] | 57 [50–66] | 58 [48–68] | 0.811 | 59 [49–68] | 59 [49–67] | 58 [48–68] | 0.660 | |
Tumor location, n (%) | 0.414 | 0.361 | |||||||
Lower | 363 (45.2) | 299 (44.9) | 64 (46.7) | 185 (45.0) | 121 (44.2) | 64 (46.7) | |||
Middle | 199 (24.8) | 161 (24.2) | 38 (27.7) | 103 (25.1) | 65 (23.7) | 38 (27.7) | |||
Upper | 241 (30.0) | 206 (30.9) | 35 (25.6) | 123 (29.9) | 88 (32.1) | 35 (25.6) | |||
Differentiated degree, n (%) | <0.001 | 0.268 | |||||||
High | 512 (63.7) | 464 (69.7) | 48 (35.0) | 161 (39.2) | 113 (41.2) | 48 (35.0) | |||
Low | 291 (36.3) | 202 (30.3) | 89 (65.0) | 250 (60.8) | 161 (58.8) | 89 (65.0) | |||
pT stage, n (%) | <0.001 | 0.163 | |||||||
pT1 | 112 (13.9) | 107 (16.0) | 5 (3.6) | 9 (2.1) | 4 (1.5) | 5 (3.6) | |||
pT2 | 100 (12.5) | 85 (12.8) | 15 (10.9) | 41 (10.0) | 26 (9.5) | 15 (10.9) | |||
pT3 | 187 (23.3) | 164 (24.6) | 23 (16.8) | 82 (20.0) | 59 (21.5) | 23 (16.8) | |||
pT4a | 294 (36.6) | 233 (35.0) | 61 (44.5) | 200 (48.7) | 139 (50.7) | 61 (44.5) | |||
pT4b | 110 (13.7) | 77 (11.6) | 33 (24.1) | 79 (19.2) | 46 (16.8) | 33 (24.2) | |||
pN stage, n (%) | <0.001 | 0.371 | |||||||
pN0 | 310 (38.6) | 294 (44.1) | 16 (11.7) | 53 (12.9) | 37 (13.5) | 16 (11.7) | |||
pN1 | 143 (17.8) | 132 (19.8) | 11 (8.0) | 34 (8.3) | 23 (8.4) | 11 (8.0) | |||
pN2 | 147 (18.3) | 106 (15.9) | 41 (29.9) | 135 (32.8) | 94 (34.3) | 41 (29.9) | |||
pN3a | 115 (14.3) | 83 (12.5) | 32 (23.4) | 102 (24.8) | 70 (25.5) | 32 (23.4) | |||
pN3b | 88 (11.0) | 51 (7.7) | 37 (27.0) | 87 (21.2) | 50 (18.3) | 37 (27.0) | |||
Chemotherapy, n (%) | 0.712 | 0.093 | |||||||
Yes | 484 (60.3) | 399 (59.9) | 85 (62.0) | 279 (67.9) | 194 (70.8) | 85 (62.0) | |||
No | 319 (39.7) | 267 (40.1) | 52 (38.0) | 132 (32.1) | 80 (29.2) | 52 (38.0) | |||
Tumor size, n (%) | <0.001 | 0.343 | |||||||
<5 cm | 451 (56.2) | 395 (59.3) | 56 (40.9) | 183 (44.5) | 127 (46.4) | 56 (40.9) | |||
≥5 cm | 352 (43.8) | 271 (40.7) | 81 (59.1) | 228 (55.5) | 147 (53.6) | 81 (59.1) |
TD, tumor deposit; PSM, propensity score matching; IQR, interquartile range.